The blood/fluid portion of the biorepository began operations in 2020 and has since processed approximately 400,000 biospecimens for clinical operations, epidemiologic surveillance of COVID-19, and multiple research projects.
The biorepository currently contains over 175,000 biospecimen aliquots including blood, sera, plasma, and viral transport media.
In addition to the banked specimens, which primarily focus on COVID-19, specimens can be acquired prospectively based on specific clinical characteristics derived from the electronic health record. This approach has been used to successfully validate multiple clinical assays and support Yale researchers across multiple departments.